Baseline molecular status | Maximum dose reduction 1 (compared to patient’s starting dose) | Maximum dose reduction 2 (compared to reduced dose) |
---|---|---|
MR3-MR4 (BCR-ABL1 levels ≤ 0.1% and 0.01% on the International Scale (IS), respectively) | 25% | 25% |
MR4.5-MR5 (BCR-ABL1 levels ≤ 0.0032% and 0.001% on the IS, respectively) | 25% | 50% |